ScripLightstone Ventures has closed its third fund – its largest to date – with $375m to fund early stage biopharmaceutical and medical technology companies after several successful exits via initial publi
ScripWho: Eli Lilly/Disarm Therapeutics What: Lilly is making its second acquisition of the year, buying privately held Disarm and its preclinical SARM1 inhibitor program for axonal degeneration indicat